Xanthopoulos Kleanthis Gabriel 4

What Happened Dr. Xanthopoulos Kleanthis Gabriel, a non‑employee director of Connect Biopharma Holdings Ltd (CNTB), was granted 3,738 fully vested ordinary shares on June 30, 2026. The filing reports an acquisition (transaction code A) of 3,738 shares at $0.00 (grant), reflecting a grant issued in lieu of part of his 2026 cash retainer rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-30 (Form 4 filed 2026-07-01 — timely within standard Form 4 reporting window).
• Transaction type/code: Award/Grant (A).
• Shares acquired: 3,738 shares; reported acquisition price: $0.00 (grant).
• Shares owned after transaction: Not disclosed in the portion of the filing provided.
• Footnote: Shares were issued under the Connect Biopharma Non‑Employee Director Compensation Program; Dr. Xanthopoulos elected to receive fully vested shares in lieu of part of his 2026 board cash retainer. The number of shares was calculated using the average closing price of the ordinary shares for the 30 days ending June 30, 2026, rounded down.
• No 10b5‑1 plan, tax‑withholding, or late‑filing issues are indicated in the provided filing.

Context This was a routine director compensation grant (equity in lieu of cash) and not an open‑market purchase or sale. Such awards are standard for non‑employee directors and represent compensation rather than a direct signal of buying or selling preference in the market.